ON THE PEN

ON THE PEN

Boehringer’s Next Obesity Bet Not Just Another Incretin, It’s One of the Brain’s Most Powerful Hunger Pathways

On The Pen GLP-1 News's avatar
On The Pen GLP-1 News
Jul 17, 2026
∙ Paid

Over the past few years, we’ve watched obesity medicines evolve from our favorite GLP-1 therapies we discuss like semaglutide, or dual agonists like tirzepatide, and now to triple agonists like retatrutide. Each generation has targeted more biological pathways than the last, and each has delivered greater weight loss by treating obesity as the complex b…

User's avatar

Continue reading this post for free, courtesy of On The Pen GLP-1 News.

Or purchase a paid subscription.
© 2026 OTP Media Corp. · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for writing, podcasting, and media founders.